Odanacatib
- Generic Name
- Odanacatib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27F4N3O3S
- CAS Number
- 603139-19-1
- Unique Ingredient Identifier
- N673F6W2VH
- Background
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.
- Indication
Investigated for use/treatment in osteoporosis .
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 214
- Registration Number
- NCT00729183
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00691899
Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 287
- Registration Number
- NCT00620113
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16071
- Registration Number
- NCT00529373
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 43
- Registration Number
- NCT00399802
A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 399
- Registration Number
- NCT00112437
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath